These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581 [TBL] [Abstract][Full Text] [Related]
4. Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life. Edin HM; Andersen LB; Schoaf L; Scott-Wilson CA; Ho SY; Ortega HG Ann Allergy Asthma Immunol; 2009 Apr; 102(4):323-7. PubMed ID: 19441604 [TBL] [Abstract][Full Text] [Related]
5. [Progress of research on pressurized metered dose inhalers]. Zhou X Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):213-5. PubMed ID: 23856147 [No Abstract] [Full Text] [Related]
6. Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma. Pinnas JL; Noonan MJ; Weinstein SF; Chervinsky P; Scott CA; Herje NE; Wu W; Crim C J Asthma; 2005 Dec; 42(10):865-71. PubMed ID: 16393726 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD. Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820 [TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group. Tonnel AB; Bons J; Legendre M; Prud'Homme A; Bugnas B; Evano-Celli I; Stuart AM Respir Med; 2000 Jun; 94 Suppl B():S29-34. PubMed ID: 10919683 [TBL] [Abstract][Full Text] [Related]
9. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler. Donnell D; Harrison LI; Ward S; Klinger NM; Ekholm BP; Cooper KM; Porietis I; McEwen J Eur J Clin Pharmacol; 1995; 48(6):473-7. PubMed ID: 8582466 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. Nelson HS; Wolfe JD; Gross G; Greos LS; Baitinger L; Scott C; Dorinsky P Ann Allergy Asthma Immunol; 2003 Sep; 91(3):263-9. PubMed ID: 14533658 [TBL] [Abstract][Full Text] [Related]
11. Short-term lower leg growth in 5- to 11-year-old asthmatic children using beclomethasone dipropionate inhalers with chlorofluorocarbon or hydrofluoroalkane propellants: a 9-week, open-label, randomized, crossover, noninferiority study. Wolthers OD; Walters EG Clin Ther; 2011 Aug; 33(8):1069-76. PubMed ID: 21784529 [TBL] [Abstract][Full Text] [Related]
12. Equivalence of salbutamol 200 microg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Eastern European study group. Salat D; Popov D; Sykes AP Respir Med; 2000 Jun; 94 Suppl B():S22-8. PubMed ID: 10919682 [TBL] [Abstract][Full Text] [Related]
13. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. Colice G; Martin RJ; Israel E; Roche N; Barnes N; Burden A; Polos P; Dorinsky P; Hillyer EV; Lee AJ; Chisholm A; von Ziegenweidt J; Barion F; Price D J Allergy Clin Immunol; 2013 Jul; 132(1):45-54. PubMed ID: 23591272 [TBL] [Abstract][Full Text] [Related]
14. Budesonide administered using chlorofluorocarbon and hydrofluoroalkane pressurized metered-dose inhalers: pharmacokinetics, pharmacodynamics and clinical equivalence. Singh D; Tutuncu A; Lohr I; Carlholm M; Polanowski T Int J Clin Pharmacol Ther; 2007 Sep; 45(9):485-95. PubMed ID: 17907591 [TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. Ayres JG; Millar AB; Sykes AP Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685 [TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Cripps A; Riebe M; Schulze M; Woodhouse R Respir Med; 2000 Jun; 94 Suppl B():S3-9. PubMed ID: 10919679 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects. Kempsford R; Handel M; Mehta R; De Silva M; Daley-Yates P Respir Med; 2005 Apr; 99 Suppl A():S11-9. PubMed ID: 15777604 [TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group. Perruchoud AP; Lundback B; Yigla M; Sykes AP Respir Med; 2000 Jun; 94 Suppl B():S35-41. PubMed ID: 10919684 [TBL] [Abstract][Full Text] [Related]